NCT07135466 2026-01-16A Phase 1/2 Study of T-cell Expressing an Anti-CD22 Chimeric-Antigen Receptor (SHB-04-CD22) in Patients With CD22-expressing B-cell MalignanciesSheba Medical CenterPhase 1/2 Recruiting50 enrolled